Accretion Pharmaceuticals Delivers Robust H1 FY27 Growth with PAT Surging 72.63% YoY
Accretion Pharmaceuticals Ltd · Investor Presentation · 03 Nov 2026, 10:55 pm
Accretion Pharmaceuticals Delivers Robust H1 FY27 Growth with PAT Surging 72.63% YoY Accretion Pharmaceuticals reported a strong performance for H1 FY27, with revenue from operations growing 25.83% YoY to ₹55.04 crore. EBITDA jumped 72.28% YoY to ₹12.37 crore as EBITDA margin expanded 606 bps to 22.48%. Net profit surged 72.63% YoY to ₹8.20 crore, expanding PAT margins by 403 bps to 14.90%. Export contribution doubled to 18.15% from 9.16% in H1 FY26. Growth was driven by an improved product mix, capacity additions, and expanding international presence across 30+ countries, alongside ongoing CAPEX for facility expansion.
Original exchange filing (PDF)
More announcements from Accretion Pharmaceuticals Ltd
- Accretion Pharmaceuticals Limited has informed the Exchange about General Updates · 16 Nov 2026
- Accretion Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 02 Nov 2026
- Accretion Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 31, 2026, titled "Company Reports 25.83% Revenue Growth and 72.63% PAT Growth in H1 FY27 and Strong EBITDA Growth of 72.28%; EBITDA Margin Improves to 22.48%". · 31 Oct 2026
- Accretion Pharmaceuticals Limited has submitted to the Exchange, the unaudited financial results for the half year ended September 30, 2026. · 31 Oct 2026
- Accretion Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 31-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 31 Oct 2026
- To consider and approve the financial results for the period ended September 30, 2026 · 31 Oct 2026
- Accretion Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Postal Ballot. Further, the company has submitted the Exchange a copy of Srutinizers report. · 12 Oct 2026
- Accretion Pharmaceuticals Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company. · 11 Oct 2026
